March 11, 2024 – Thermo Fisher Scientific Inc. has introduced the launch of a brand new CorEvitas syndicated medical registry for generalized pustular psoriasis (GPP). This register, which is open for registration, is CorEvitas' 10^e syndicated illness registry and addresses an unmet want for real-world proof (RWE) relating to the medical and patient-reported outcomes of sufferers with GPP.

The brand new registry will prospectively accumulate detailed patient-level information, permitting evaluation of the pure historical past of the illness and therapy patterns, together with the prevalence and incidence of comorbidities in sufferers with the illness. Detailed, longitudinal end result measures might be collected throughout registry visits, a few of which can embody physician-reported GPP outcomes, laboratory measures, and therapy historical past, in addition to patient-reported outcomes assessing symptom influence and high quality of life. Information on drug security may even be collected, together with severe unintended effects and different unintended effects of specific concern.

Study extra